Incretin-based Combination Therapy in Type 2 Diabetes Mellitus
Journal of the Korean Medical Association
;
: 1030-1036, 2009.
Article
in Korean
| WPRIM
| ID: wpr-154386
ABSTRACT
While there are many therapies for type 2 diabetes are available including insulin secretagogues, insulin sensitizers and exogenous insulin, many patients are unable to reach recommended therapeutic targets. Incretin-based therapies have recently been introduced into clinical practice, and these novel therapies may make it possible to achieve improved glycemic control either with no weight gain (dipeptidyl peptidase-4 [DPP-4] inhibitors sitagliptin and vildagliptin, or with weight loss (glucagon-like peptide-1 [GLP-1] mimetics exenatide and liraglutide). This article aims to provide an overview of efficacy and safety data regarding incretinbased clinical trials in type 2 diabetic patients, and propose a systematic approach to treatment including patient selection and optimal treatment combination. In addition, preclinical data suggest that incretin-based therapies may also preserve-cell function. Therefore, these agents hold out promise of a truly disease-modifying therapy that would target the progressive nature of type 2 diabetes. Additional clinical trials will be required to test such hypothesis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Peptides
/
Pyrazines
/
Pyrrolidines
/
Triazoles
/
Venoms
/
Adamantane
/
Weight Gain
/
Weight Loss
/
Patient Selection
/
Diabetes Mellitus, Type 2
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Medical Association
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS